Irr itable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract characterized by recurrent episodes of abdominal pain or discomfort along with changes in frequency or consistency of the stool in the absence of an organic etiology. The condition is heterogeneous, exhibiting variability in the frequency of symptoms reported within and between males and females. 1 The pathophysiological mechanisms of IBS are not completely understood. Alterations in gut motility, visceral perception, and central processing of pain and motor function due to abnormalities in the enteric and central nervous system are believed to account for symptoms of IBS. 2 The brain-gut axis and biopsychosocial model have been used to explain how intrinsic and extrinsic stimuli modulate disease expression. 3, 4 It is unknown whether IBS is primarily a disorder of abnormal perception to a normal stimulus, or a disorder of normal perception to an abnormal physiologic sensory stimulus. Since no structural abnormalities or biochemical markers characterize IBS, diagnosis is based on the presence of clinical symptoms. 2 Symptom-based diagnostic criteria have been established to create uniformity in reporting and enhance diagnostic accuracy. Objective: The quality of documentation of signs and symptoms and validation of the diagnosis of irritable bowel syndrome (IBS) according to case definition criteria of Manning, Rome I and Rome II in an office setting has not been previously described.We sought to identify and validate cases of IBS based on the Manning, Rome I and Rome II diagnostic criteria in a rural practice setting. 
All diagnostic criteria used to differentiate IBS from organic diseases are self-reported measures of abdominal pain and bowel habits (table 1) . [5] [6] [7] [8] The diagnosis of IBS is confirmed by applying symptom-based criteria and pursuing further diagnostic evaluations to exclude organic diseases, as needed. Symptom-based criteria should be individualized, taking into account the patient's age, associated conditions, duration of symptoms, previous diagnostic evaluations, severity of symptoms, travel history and lactose consumption.
Criteria used to establish the diagnosis of IBS have evolved since the initial work of Manning et al 5 in 1978 and reflect a better understanding of the symptomatology associated with this disease. The Rome I and II criteria reflect more specific clinical diagnostic standards than the Manning criteria. 9 Thus, many patients previously diagnosed with IBS under the Manning criteria would not receive a diagnosis of IBS based on the most recent Rome criteria. However, if the more restrictive case definitions of the Rome I and II criteria are applied, patients with IBS may potentially be underdiagnosed. 10, 11 Previous studies evaluating case definitions were based on surveys and are limited by the diagnostic criteria used, the questions asked and the ethnicity and cultural background of the population sampled. 9, 10, 12 In this retrospective study, we utilized data from medical records to evaluate the diagnosis of IBS in a population-based cohort within a clinical practice. The quality of medical record documentation of clinical symptoms of IBS was determined, and IBS diagnoses were validated based on the Manning, Rome I and Rome II criteria. These three alternative criteria used to diagnose IBS were compared in terms of biennial age-and gender-adjusted incidence rates beginning from January 1, 1993 through December 31, 2003 per 100,000 person-years. Percent concordance of each paired comparison of criteria-based IBS was also determined.
Methods

Setting
The central region of the Marshfield Epidemiologic Study Area (MESA) is a select geographic region of 14 ZIP codes in central Wisconsin where nearly all of the approximately 60,000 residents receive their medical care from Marshfield Clinic and affiliated hospitals. The city of Marshfield represents the approximate center of MESA Central and is home to 18,900 residents. Marshfield is the only community in MESA with a population greater than 4,000. The remainder of the MESA Central population lives in areas designated as "rural," as defined by the Federal Office of Management and Budget. According to the 2000 United States Census, the population residing in MESA Central was 97% nonHispanic, white.
MESA validation studies have shown that over a third of the people moving out of the study area stay within Marshfield Clinic's broader service area and continue to obtain care from 
Inclusion Criteria
Patients were included in this study if they were >18 years of age and resided in MESA Central at the time of their initial diagnosis of IBS during odd-numbered years from January 1, 1993 through December 31, 2003. Odd-numbered years were chosen to maximize the study interval surveyed, within the constraints of funding available. Patients were excluded if diagnosed with an organic disease that was associated with similar symptoms (e.g., Crohn's disease, ulcerative colitis, celiac sprue or colon cancer) within 12 months of the IBS diagnosis.
Chart Abstraction
Medical records of Marshfield Clinic patients initially diagnosed with IBS were retrospectively reviewed to validate the diagnosis of IBS made at the time the ICD-9 code for IBS was assigned (reference date). Data abstracted included the date of initial diagnosis of IBS, symptoms 12 months prior to the reference date, laboratory and procedural information 12 months prior to the reference date and diagnoses made 12 months after the first diagnosis of IBS to determine whether there was any change to an alternative diagnosis. Demographic characteristics (i.e., age and gender), specialties of the physicians making the diagnoses, dates of last clinical follow-up with symptoms of IBS, referrals to a gastroenterologist within 3 months of first diagnosis of IBS, and bowel patterns (e.g., constipation, diarrhea, alternating diarrhea and constipation) were also abstracted. Duration, frequency and/or intensity of symptoms of diarrhea, abdominal pain, cramping, discomfort, distention, bloating, constipation, change in stool habits, pain relief with defecation, stool frequency (i.e., >3 or <3 bowel movements/day, >3 or <3 bowel movements/week), stool characteristics (e.g., lumpy, hard, watery, loose, with and without pain, presence of mucus), incomplete evacuation, straining and urgency were ascertained. The duration of symptoms was recorded to ensure that they met the duration criteria specified in the Rome I and II criteria. Quality assurance procedures included an independent re-abstraction of a 10% sample of all charts to validate the accuracy of the abstraction.
Statistical Methods
Abstracted data were used to subset each of the phenotypic groupings, but no statistical tests were performed due to case overlap among the groups. Biennial age-and genderadjusted incidence rates per 100,000 person-years and corresponding 95% upper and lower confidence intervals (CI) were calculated for validated, definitive cases based on each diagnostic criterion. Case definition criteria based on documented clinical symptoms identified 404 patients who met one or more of the diagnostic criteria. Consistent with findings of previous studies, the initial IBS diagnosis was made primarily by primary care physicians. 15 The fact that only 404/890 cases (45%) met one or more of the diagnostic criteria suggests that primary care physicians may not be aware of the Manning or Rome criteria, fail to recognize or inquire about the symptoms associated with the diagnostic criteria, do not appropriately utilize the diagnostic criteria, or the diagnostic criteria have limitations relative to clinical application. [15] [16] [17] [18] Unlike the Manning criteria, the Rome I and II criteria include a specification regarding the percentage of time that symptoms need to be present. Thus, Rome I and II criteria are more conservative and less inclusive compared to the Manning criteria. Furthermore, Rome II criteria appeared more restrictive than the Rome I criteria despite the simplicity of their design. On assessing utility of Rome I and II criteria, Chey et al 11 found that Rome I criteria had higher sensitivity compared to Rome II for the diagnosis of IBS. Thus, patients diagnosed with IBS using Rome I may not fulfill the Rome II criteria. 19 In the general population, the Rome I and II criteria identify similar proportions of persons with IBS. However, in a clinical setting, the Rome II criteria identify a smaller number of patients compared to the Rome I criteria. 2, 9, 18 The fact that no patients in this study fulfilled Rome I and II criteria alone may relate to their original design as epidemiological screening tools for identifying patients meeting clinical trial eligibility requirements. 4 Hence, their applicability as clinical practice-based tools for evaluating IBS may be limited. 19, 20 In follow-up studies, the Rome and Manning criteria have been associated with accurate IBS diagnoses. Once the diagnosis is confirmed by either Manning or Rome criteria and limited investigations are negative, diagnostic reclassification seldom occurs. 18, 21, 22 Our results confirmed this finding: only 13 initial diagnoses were reclassified over the 12 month observational period.
We reported the rate of clinical diagnosis as a surrogate for true incidence. True incidence of IBS could not be accurately ascertained due to the clinical nature of this study, and we postulated that the more severe cases of IBS who sought medical care were those captured in the present study. Furthermore, Rome II criteria were designed to define a more homogenous population, and therefore, likely underestimate the incidence of IBS. 19 Age-and gender-adjusted biennial incidence rates for definitive cases of IBS were reported between 1993 and 2003.
Historically, incidence data derived from patient office visits ranged from 196 to 250 cases per 100,000 person-years. 20, 23 We found a similar crude incidence rate of 128 to 250 (CI lower: 93-199, upper: 163-302) based on symptomology documented in the medical record for odd numbered years, with lower rates based on specific diagnostic criteria. Population-based surveys project that approximately 9% of the general population will have an onset of IBS symptoms over a 1-year period. 24 Overall, when persons with any previous symptoms are excluded, the true incidence rate probably ranges from 1% to 2%. 25 Unlike previous studies that have reported female-to-male ratios as high as 3:1, our study documented a ratio of femalesto-males of approximately 2:1, respectively. We were not able to determine period prevalence estimates in our population, since our validation efforts of the oddnumbered years indicated that we could not rely on the ICD-9 codes for a definitive IBS diagnosis and available funds did not allow us to validate ICD-9 code data prior to January 1, 1993 or during even-numbered years. We also recognize the limited accuracy of the ICD-9 codes for identifying patients with a definitive diagnosis of IBS based on case definition criteria, which further limited our ability to determine prevalence since IBS is a heterogeneous condition whose diagnosis relies on documentation of symptoms. The retrospective design of our study would likely cause incidence estimates to underestimate the true MESA incidence of IBS due to potential inaccuracies in the documentation of symptoms in the medical record or lack of ICD-9 code assignment to potentially positive IBS cases. A major strength of this study was that it was population-based and independent of self-administered questionnaires to define IBS. The extent of population coverage and health information captured using a resource, such as the MESA database, minimizes reporting and referral bias. However, limiting the study to the MESA population of which 97% are Caucasian poses obvious limitations on the generalizability of the findings.
In conclusion, the diagnosis of irritable bowel syndrome (IBS) is currently based on symptomatic criteria that exclude other conditions affecting the gastrointestinal tract, such as celiac disease, food allergies, and infections. The absence of appropriate diagnostic and therapeutic approaches for IBS places a significant burden on the patient and the health care system due to direct and indirect costs of care. [34] [35] [36] Symptomatic criteria are often used inappropriately and are limited to specific populations. The absence of alarm symptoms (e.g. unintentional weight loss, rectal bleeding) in patients who meet diagnostic criteria may not necessitate routinely ordering further laboratory tests or pursuing further diagnostic evaluation. 36, 37 Our study demonstrated that only a small percentage (45%) of IBS-coded diagnoses actually met the case definition for IBS. Reasons underlying this could include poor documentation of symptoms, absence of symptoms, or failure of clinicians to inquire about symptoms. A low concordance rate between the three diagnostic criteria was further observed and was likely attributable to the more restrictive Rome I and II criteria. 
